Tom 16, Nr 2 (2019)
Prewencja
Opublikowany online: 2019-06-27

dostęp otwarty

Wyświetlenia strony 2240
Wyświetlenia/pobrania artykułu 5761
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Produkty tytoniowe oparte na podgrzewaniu tytoniu (heat-not-burn) a zdrowie pacjentów — opinia grupy ekspertów

Filip M. Szymański1, Piotr Kuna2, Anna E. Płatek13, Robert Kowalik1, Joann Gotlib4, Krzysztof J. Filipiak1
Choroby Serca i Naczyń 2019;16(2):135-142.

Streszczenie

Nikotynizm jest jednym z uznanych i szeroko zbadanych czynników ryzyka chorób układu sercowo-naczyniowego oraz zgonu. Palenie papierosów stanowi również jeden z najistotniej- szych czynników ryzyka zachorowań oraz zgonu z powodu chorób serca i naczyń krwionośnych. Mimo dostępności wielu metod wspomagających leczenie uzależnienia od tytoniu ich skuteczność pozostaje niewystarczająca. Alternatywę dla palenia papierosów mogą stanowić produkty tytoniowe oparte na podgrzewaniu tytoniu, których stosowanie może się łączyć z niższym ryzykiem sercowo-naczyniowym. W niniejszym artykule przedstawiono podsumowanie aktualnego stanu wiedzy i zaleceń polskich ekspertów w zakresie bezpieczeństwa stosowania tych produktów.

Artykuł dostępny w formacie PDF

Pokaż PDF Pobierz plik PDF

Referencje

  1. Piepoli MF, Hoes AW, Agewall S, et al. ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016; 37(29): 2315–2381.
  2. Doll R, Peto R, Boreham J, et al. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ. 2004; 328(7455): 1519.
  3. Kiiskinen U, Vartiainen E, Puska P, et al. Long-term cost and life-expectancy consequences of hypertension. J Hypertens. 1998; 16(8): 1103–1112.
  4. Prescott E, Hippe M, Schnohr P, et al. Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ. 1998; 316(7137): 1043–1047.
  5. Benowitz NL. Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. Prog Cardiovasc Dis. 2003; 46(1): 91–111.
  6. Henningfield JE, Stapleton JM, Benowitz NL, et al. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend. 1993; 33(1): 23–29.
  7. Benowitz NL, Kuyt F, Jacob P, et al. Circadian blood nicotine concentrations during cigarette smoking. Clin Pharmacol Ther. 1982; 32(6): 758–764.
  8. Benowitz NL, Jacob P, Denaro C, et al. Stable isotope studies of nicotine kinetics and bioavailability. Clin Pharmacol Ther. 1991; 49(3): 270–277.
  9. Allred EN, Bleecker ER, Chaitman BR, et al. Short-term effects of carbon monoxide exposure on the exercise performance of subjects with coronary artery disease. N Engl J Med. 1989; 321(21): 1426–1432.
  10. Calverley PM, Leggett RJ, Flenley DC. Carbon monoxide and exercise tolerance in chronic bronchitis and emphysema. Br Med J (Clin Res Ed). 1981; 283(6296): 878–880.
  11. Church DF, Pryor WA. Free-radical chemistry of cigarette smoke and its toxicological implications. Environ Health Perspect. 1985; 64: 111–126.
  12. Lykkesfeldt J, Christen S, Wallock LM, et al. Ascorbate is depleted by smoking and repleted by moderate supplementation: a study in male smokers and nonsmokers with matched dietary antioxidant intakes. Am J Clin Nutr. 2000; 71(2): 530–536.
  13. Morrow JD, Frei B, Longmire AW, et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med. 1995; 332(18): 1198–1203.
  14. Burke A, Fitzgerald GA. Oxidative stress and smoking-induced vascular injury. Prog Cardiovasc Dis. 2003; 46(1): 79–90.
  15. Taylor TLD, Bryant A, Keyse L, Joloza MT. Smoking-related behaviour and attitudes, 2005. Office for National Statistics, London 2006.
  16. Prescott E, Scharling H, Osler M, et al. Importance of light smoking and inhalation habits on risk of myocardial infarction and all cause mortality. A 22 year follow up of 12 149 men and women in The Copenhagen City Heart Study. J Epidemiol Community Health. 2002; 56(9): 702–706.
  17. Kotseva K, Wood D, De Backer G, et al. EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009; 16(2): 121–137.
  18. Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE Investigators. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016; 23(6): 636–648.
  19. Stead LF, Bergson G, Lancaster T. Physician advice for smoking cessation. Cochrane Database Syst Rev. 2008(2): CD000165.
  20. Heatherton TF, Kozlowski LT, Frecker RC, et al. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991; 86(9): 1119–1127.
  21. Barboza JL, Patel R, Patel P, et al. An update on the pharmacotherapeutic interventions for smoking cessation. Expert Opin Pharmacother. 2016; 17(11): 1483–1496.
  22. Hajek P, Phillips-Waller A, Przulj D, et al. A randomized trial of E-cigarettes versus nicotine-replacement therapy. N Engl J Med. 2019; 380(7): 629–637.
  23. Simonavicius E, McNeill A, Shahab L, et al. Heat-not-burn tobacco products: a systematic literature review. Tob Control. 2018 [Epub ahead of print].
  24. Haziza C, de La Bourdonnaye G, Merlet S, et al. Assessment of the reduction in levels of exposure to harmful and potentially harmful constituents in Japanese subjects using a novel tobacco heating system compared with conventional cigarettes and smoking abstinence: A randomized controlled study in confinement. Regul Toxicol Pharmacol. 2016; 81: 489–499.
  25. Haziza C, de La Bourdonnaye G, Skiada D, et al. Evaluation of the Tobacco Heating System 2.2. Part 8: 5-Day randomized reduced exposure clinical study in Poland. Regul Toxicol Pharmacol. 2016; 81 Suppl 2: S139–S150.
  26. Gale N, McEwan M, Eldridge A, et al. Changes in biomarkers of exposure on switching from a conventional cigarette to tobacco heating products: a randomized, controlled study in healthy Japanese subjects. Nicotine Tob Res. 2018.
  27. Cappelleri JC, Bushmakin AG, Baker CL, et al. Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. Addict Behav. 2007; 32(5): 912–923.
  28. Haziza C, de La Bourdonnaye G, Merlet S, et al. Assessment of the reduction in levels of exposure to harmful and potentially harmful constituents in Japanese subjects using a novel tobacco heating system compared with conventional cigarettes and smoking abstinence: A randomized controlled study in confinement. Regul Toxicol Pharmacol. 2016; 81: 489–499.
  29. Haziza C, de La Bourdonnaye G, Donelli A, et al. Effects of switching to the Tobacco Heating System 2.2 Menthol, smoking abstinence, or continued cigarette smoking on biomarkers of exposure: a randomized, controlled, open-label, multicenter study in sequential confinement and ambulatory settings (part 1). Nicotine Tob Res. 2018; 20(2): 161–172.
  30. Lüdicke F, Magnette J, Baker G, et al. A Japanese cross-sectional multicentre study of biomarkers associated with cardiovascular disease in smokers and non-smokers. Biomarkers. 2015; 20(6-7): 411–421.
  31. Lüdicke F, Picavet P, Baker G, et al. Effects of switching to the Menthol Tobacco Heating System 2.2, smoking abstinence, or continued cigarette smoking on clinically relevant risk markers: a randomized, controlled, open-label, multicenter study in sequential confinement and ambulatory settings (part 2). Nicotine & Tobacco Research. 2017; 20(2): 173–182.
  32. Mallock N, Böss L, Burk R, et al. Levels of selected analytes in the emissions of "heat not burn" tobacco products that are relevant to assess human health risks. Arch Toxicol. 2018; 92(6): 2145–2149.
  33. http://www.koreaherald.com/view.php?ud=20190127000090 (23.04.2019).
  34. https://apps.who.int/iris/bitstream/handle/10665/273459/WHO-NMH-PND-18.7-eng.pdf (23.04.2019).
  35. https://gis.gov.pl/wp-content/uploads/2018/04/Postawy-Polak%C3%B3w-do-palenia-tytoniu-Raport-2017.pdf (23.04.2019).
  36. Streszczenie Raportu Światowej Organizacji Zdrowia WHO. www.who.un.org.pl/common/files_download.php?fid=33 (23.04.2019).
  37. Smith TT, Hatsukami DK, Benowitz NL, et al. Whether to push or pull? Nicotine reduction and non-combusted alternatives - Two strategies for reducing smoking and improving public health. Prev Med. 2018; 117: 8–14.
  38. Yang YT. FDA's regulatory shift on tobacco control. Prev Med. 2018; 113: 153–155.
  39. https://assets publishing service gov uk/government/uploads/system/uploads/attachment_data/file/684963/Evidence_review_of_e-cigarettes_and_heated_tobacco_products (23.04.2019).
  40. https://pathways.nice.org.uk/pathways/smoking-tobacco-harm-reduction-approaches (23.04.2019).
  41. https://publications parliament uk/pa/cm201719/cmselect/cmsctech/505 (23.04.2019).
  42. https://cot.food.gov.uk/sites/default/files/heat_not_burn_tobacco_statement.pdf (https://publications parliament uk/pa/cm201719/cmselect/cmsctech/505).
  43. WHO Study Group on Tobacco Product Regulation: Report on the Scientific Basis of Tobacco Product Regulations. Fifth Report of a WHO Study Group. Technical Report Series 989. World Health Organization, Geneva, Switzerland.. Assessment of novel tobacco heating product THP1.0. Part 3. In: Forster M, Fiebelkorn S, Yurteri C. ed. Report on the scientific basis of tobacco product regulations. Fifth report of a WHO Study Group. Technical Report Series 989. World Health Organization, Geneva 2015.
  44. Comprehensive chemical characterisation of harmful and potentially harmful aerosol emissions. Regul Toxicol Pharmacol. 2018; 93: 131.
  45. Schaller JP, Keller D, Poget L, et al. Evaluation of the Tobacco Heating System 2.2. Part 2: Chemical composition, genotoxicity, cytotoxicity, and physical properties of the aerosol. Regul Toxicol Pharmacol. 2016; 81 Suppl 2: S27–S47.
  46. Caputi TL, Leas E, Dredze M, et al. They're heating up: Internet search query trends reveal significant public interest in heat-not-burn tobacco products. PLoS One. 2017; 12(10): e0185735.
  47. Marynak KL, Wang TW, King BA, et al. Awareness and ever use of "heat-not-burn" tobacco products among U.S. Adults, 2017. Am J Prev Med. 2018; 55(4): 551–554.
  48. https://www.chemikalia.gov.pl/monitorowanie_rynku_epapierosow.html (23.04.2019).